6-[(7-硝基-2,1,3-苯并恶二唑-4-基)氨基]己酸结构式
|
常用名 | 6-[(7-硝基-2,1,3-苯并恶二唑-4-基)氨基]己酸 | 英文名 | 6-((7-NITROBENZO[C][1,2,5]OXADIAZOL-4-YL)AMINO)HEXANOIC ACID |
---|---|---|---|---|
CAS号 | 88235-25-0 | 分子量 | 294.26300 | |
密度 | 1.462 | 沸点 | 559.4ºC at 760 mmHg | |
分子式 | C12H14N4O5 | 熔点 | N/A | |
MSDS | 中文版 美版 | 闪点 | N/A | |
符号 |
GHS06 |
信号词 | Danger |
用途NBD-X酸是研究脂肪酸和甾醇的荧光探针。与NBD氯化物和氟化物相比,NBD-X酸为标记生物聚合物提供了更好的产率。NBD衍生物的荧光光谱对环境高度敏感,在水溶液中荧光强度显著降低[1]。 |
中文名 | 6-[(7-硝基-2,1,3-苯并恶二唑-4-基)氨基]己酸 |
---|---|
英文名 | 7-nitrobenzoxadiazole-6-aminohexanoic acid |
中文别名 | NBD-X酸 | 6-(7-硝基-2,1,3-苯并恶二唑-4-基氨基)己酸 |
英文别名 | 更多 |
描述 | NBD-X酸是研究脂肪酸和甾醇的荧光探针。与NBD氯化物和氟化物相比,NBD-X酸为标记生物聚合物提供了更好的产率。NBD衍生物的荧光光谱对环境高度敏感,在水溶液中荧光强度显著降低[1]。 |
---|---|
相关类别 | |
参考文献 |
密度 | 1.462 |
---|---|
沸点 | 559.4ºC at 760 mmHg |
分子式 | C12H14N4O5 |
分子量 | 294.26300 |
精确质量 | 294.09600 |
PSA | 134.07000 |
LogP | 2.78410 |
折射率 | 1.65 |
储存条件 | -20°C,密闭,干燥 |
符号 |
GHS06 |
---|---|
信号词 | Danger |
危害声明 | H301 + H311 + H331-H315-H319-H335 |
警示性声明 | Missing Phrase - N15.00950417-P261-P280-P302 + P352 + P312-P304 + P340 + P312-P403 + P233 |
个人防护装备 | Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges |
危害码 (欧洲) | T: Toxic; |
风险声明 (欧洲) | R23/24/25 |
安全声明 (欧洲) | 22-26-36-45 |
危险品运输编码 | UN 2811 6.1 / PGIII |
海关编码 | 2934999090 |
~64% 6-[(7-硝基-2,1,3-... 88235-25-0 |
文献:Novotny, Jakub; Pospechova, Katerina; Hrabalek, Alexandr; Cap, Robert; Vavrova, Katerina Bioorganic and Medicinal Chemistry Letters, 2009 , vol. 19, # 24 p. 6975 - 6977 |
~% 6-[(7-硝基-2,1,3-... 88235-25-0 |
文献:Organic Letters, , vol. 7, # 6 p. 1177 - 1180 |
~% 6-[(7-硝基-2,1,3-... 88235-25-0 |
文献:Organic Letters, , vol. 7, # 6 p. 1177 - 1180 |
海关编码 | 2934999090 |
---|---|
中文概述 | 2934999090. 其他杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0% |
申报要素 | 品名, 成分含量, 用途 |
Summary | 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
A cyclic GB virus C derived peptide with anti-HIV-1 activity targets the fusion peptide of HIV-1
Eur. J. Med. Chem. 86 , 589-604, (2014) The development of peptide fusion inhibitors based on short synthetic peptides represents a promising option in the fight against HIV-1 infection, especially in individuals infected with multiresistan... |
|
Probing the ligand binding sites of fatty acid and sterol carrier proteins: effects of ethanol.
Biochemistry 34 , 11919, (1995) Direct effects of ethanol on the interaction of cytosolic lipid transfer proteins with ligands are not known. In this study, recombinant liver fatty acid binding protein (L-FABP) and sterol carrier pr... |
|
Multidrug resistance protein 1 regulates lipid asymmetry in erythrocyte membranes.
Biochem. J. 350 Pt 2 , 531-5, (2000) The role of multidrug resistance protein 1 (MRP1) in the maintenance of transbilayer lipid asymmetry in the erythrocyte membrane was investigated. The transbilayer distribution of endogenous phospholi... |
7-Nitrobenzoxadiazole-6-aminohexanoic acid |
N-(7-Nitro-2,1,3-benzoxadiazol-4-yl)-6-aminohexanoic acid |
6-(7-Nitrobenzofurazan-4-ylamino)hexanoic acid |
N-(4-nitrobenz-2-oxa-1,3-diazol-7-yl)aminocaproic acid |
Nbd-amha |
6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanoic acid |
NBD-X |
NBD Hexanoic Acid |
6-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)hexanoic acid |
6-(7-Nitro-2,1,3-benzoxadiazol-4-ylamino)hexanoic acid |
N-(7-nitrobenz-2-oxa-1,3-diazole-4-yl)aminocaproic acid |
6-((7-Nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)hexanoic acid |